Challenges in Developing New Tuberculosis Vaccines
Author Information
Author(s): Michael J Brennan, Uli Fruth, Julie Milstien, Rosemary Tiernan, Sergio de Andrade Nishioka, Liliana Chocarro
Hypothesis
What are the regulatory challenges for testing and introducing investigative TB vaccines into countries where the disease is endemic?
Conclusion
The article discusses the need for a global regulatory framework to facilitate the development and approval of new tuberculosis vaccines.
Supporting Evidence
- Regulatory authorities from developing countries should be actively engaged in both product and clinical review of TB vaccines being investigated within their nation.
- Multi-center clinical trials are important to generate data that can be extrapolated to diverse populations.
- Global mechanisms are needed for sharing information among regulatory authorities involved in TB vaccine development.
Takeaway
We need better rules and teamwork to help create and test new vaccines for tuberculosis, especially in countries where the disease is common.
Methodology
The article summarizes discussions from a meeting of regulators, investigators, and clinicians regarding the regulatory challenges in TB vaccine development.
Limitations
The article does not provide specific data or results from clinical trials.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website